IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Noujaim

Serial No.: 09/779,439

Filed: February 8, 2001

Entitled: METHOD FOR DIAGNOSING EFFICACY OF XENOTYPIC ANTIBODY THERAPY

Examiner: L. Helms

Group Art Unit: 1642

Attorney Docket: ALT-006US1 (1009/007)

Assistant Commissioner for Patents
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Claims 1-25 are pending in this application, and stand subject to a Restriction Requirement mailed April 25, 2002. A Petition for One-Month Extension of time up to and including June 25, 2002 along with the requisite fee is enclosed.

Applicants elect Claims 22-25, drawn to a method of diagnosing the efficacy of antibody mediated immunotherapy by measuring the level of a T cell response, classified in class 435, subclass 7.1.

If there are any questions, please contact the undersigned at the telephone number indicated below.

Respectfully submitted,

Date: 6/21/02

Wayne A. Keown, Ph.D.
Reg. No. 33,923
500 West Cummings Park
Suite 2900
Woburn, MA 01801
781-938-1805 (Telephone)
781-938-4777 (Facsimile)

Amdt A/#14
3.14.03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Antoine Noujaim

Serial No: 09/779,439

Filed: February 8, 2001

For: METHOD FOR DIAGNOSING EFFICACY OF XENOTYPIC ANTIBODY THERAPY

Attorney Docket No. AREX-P01-006

Art Unit: 1642

Examiner: L.R. Helms

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

February 7, 2003
Date of Signature and of Mail Deposit

Andrea Berlo
Andrea Berlo

Commissioner for Patents
Washington, D.C. 20231

REPLY UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding non-final Office Action, mailed September 11, 2002, in connection with the above application.

Please enter the following amendments:

In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

Sub B1
A1

22. (Amended) A method for diagnosing the efficacy of a xenotypic antibody-mediated immunotherapy comprising measuring the level of a T cell response produced by a patient that has a disease associated with an antigen to which the antibody binds, wherein the T cell response produced to such antigen after administration of the xenotypic antibody to the patient relative to the level of the